May 14, 2013

Zr-89 bevacizumab could be a player in PET detection of breast cancer

May 13, 2013, Molecular Imaging,

Kathy Fay Mahdoubi reported on an article appearing in this month’s Journal Of Nuclear Medicine examining a new PET monoclonal antibody tracer Zr-89 bevacizumab for the assessment of early to late stage primary breast cancer malignancy.